Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye in connection with a capital procurement of MSEK 220
Mandate

Vinge advises Smart Eye in connection with a capital procurement of MSEK 220

November 01, 2021 Capital Markets and Public M&A

Vinge has advised Smart Eye Aktiebolag in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 220 to Smart Eye.

The subscription price of SEK 183 SEK, which corresponded to the closing price on Nasdaq First North Growth Market, was determined through an accelerated book-building procedure arranged by Carnegie. The proceeds will primarily be used to finance the acquisition of iMotions A/S, which was published on the same day.

Vinge’s team primarily consisted of Anders Strid, Edin Agic, Oscar Lunde and Adrian Filipovic.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026